Reginald Seeto Biography and Net Worth

Insider of CareDx

Dr. Seeto is an experienced leader and has held executive leadership roles in both biotech and large pharma and across a broad range of functions. Before joining CareDx, Dr. Seeto was Chief Operating Officer at Ardelyx leading pre-launch efforts for tenapanor and corporate development where he completed a series of partnerships. Prior to this, Dr. Seeto worked at AstraZeneca/Medimmune and was a member of the MedImmune Executive Team. His responsibilities included leading corporate development and strategy, global strategic marketing and portfolio management for all therapeutic areas, as well as a country leadership role at AstraZeneca in Thailand. He started his career as a physician, during which time he performed a medical rotation in a renal transplant unit, before joining McKinsey and Company.

What is Reginald Seeto's net worth?: The estimated net worth of Reginald Seeto is at least $9.88 million as of October 2nd, 2023. Dr. Seeto owns 479,164 shares of CareDx stock worth more than $9,875,570 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Seeto may own. Learn More about Reginald Seeto's net worth.
How do I contact Reginald Seeto?: The corporate mailing address for Dr. Seeto and other CareDx executives is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. CareDx can also be reached via phone at (415) 287-2300 and via email at [email protected]. Learn More on Reginald Seeto's contact information.
Has Reginald Seeto been buying or selling shares of CareDx?: Reginald Seeto has not been actively trading shares of CareDx during the last quarter. Most recently, Reginald Seeto sold 2,818 shares of the business's stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $6.91, for a transaction totalling $19,472.38. Following the completion of the sale, the insider now directly owns 479,164 shares of the company's stock, valued at $3,311,023.24. Learn More on Reginald Seeto's trading history.
Who are CareDx's active insiders?: CareDx's insider roster includes Paul Adler (CEO), George Bickerstaff, III (Director), Ankur Dhingra (CFO), Michael Goldberg (Director), William Hagstrom (Director), Sasha King (CMO), Peter Maag (Insider), Reginald Seeto (Insider), Ralph Snyderman (Director), and Thomas Thomas (Director). Learn More on CareDx's active insiders.
Are insiders buying or selling shares of CareDx?: In the last twelve months, insiders at the sold shares 4 times. They sold a total of 96,340 shares worth more than $3,150,415.19. The most recent insider tranaction occured on November, 26th when Director Peter Maag sold 5,000 shares worth more than $125,000.00. Insiders at CareDx own 4.9% of the company. Learn More about insider trades at CareDx.
Information on this page was last updated on 11/26/2024.

Reginald Seeto Insider Trading History at CareDx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/2/2023	Sell	2,818	$6.91	$19,472.38	479,164
9/5/2023	Sell	2,819	$9.49	$26,752.31	481,982
8/14/2023	Sell	576	$8.89	$5,120.64	484,801
8/2/2023	Sell	2,819	$11.35	$31,995.65	486,051
7/13/2023	Sell	5,260	$10.33	$54,335.80	488,870
7/3/2023	Sell	2,818	$8.48	$23,896.64	498,055
6/28/2023	Sell	14,268	$8.76	$124,987.68	500,873
6/2/2023	Sell	2,819	$8.13	$22,918.47	532,177
5/2/2023	Sell	2,819	$8.12	$22,890.28	534,996
4/3/2023	Sell	2,818	$8.95	$25,221.10	537,815
3/2/2023	Sell	2,819	$15.88	$44,765.72	540,633
2/9/2023	Sell	11,094	$16.13	$178,946.22	551,940
2/7/2023	Sell	3,069	$16.40	$50,331.60	563,034
2/2/2023	Sell	2,819	$17.15	$48,345.85	575,803
1/3/2023	Sell	2,818	$11.69	$32,942.42	268,906
3/21/2022	Sell	2,888	$40.43	$116,761.84
3/1/2022	Sell	3,153	$38.62	$121,768.86
2/9/2022	Sell	2,550	$45.00	$114,750.00
2/4/2022	Sell	4,988	$40.34	$201,215.92
2/1/2022	Sell	814	$42.13	$34,293.82
1/18/2022	Sell	1,719	$40.07	$68,880.33
8/27/2021	Sell	658	$80.00	$52,640.00
7/8/2021	Sell	5,994	$85.67	$513,505.98	136,748
6/28/2021	Sell	13,212	$95.75	$1,265,049.00	135,618
3/1/2021	Sell	10,704	$85.45	$914,656.80
12/18/2020	Sell	8,363	$68.01	$568,767.63	114,745

Reginald Seeto Buying and Selling Activity at CareDx

CareDx Company Overview

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Today's Range

Now: $20.61

$20.10

$21.15

50 Day Range

MA: $23.54

$20.40

$31.31

2 Week Range

Now: $20.61

$7.42

$34.84

Volume

1,790,619 shs

Average Volume

887,120 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.